Presentation

0 Comments

6 January 2017

Oral anticoagulation therapy in the long term management of ACS – beyond platelet inhibition

Andre Schmidt

Bayer's Vice President of Medical Affairs on oral anticoagulation in the long-term management of ACS

Previous | Next
Download

Summary

In this ‘Questions to Industry’ Session Bayer’s Vice President of Medical Affairs discusses the role of oral anticoagulation in the long-term management of ACS. Recent data from the ATLAS ACS 2 TIMI 51 trial are presented. In this placebo-controlled trial, Aspirin-only was compared with Aspirin+Rivaroxaban 2.5 mg bid and Aspirin+Rivaroxaban 5 mg bid for secondary prevention of ischaemic events in 15,526 patients post-ACS. 93% of patients were on a concomitant thienopyridine.  Both arms of the Rivaroxaban group saw an improvement in the primary efficacy outcome of CV death, MI or Stroke, HR=0.84 (0.72–0.97) p=0.02 and HR=0.85 (0.73–0.98) p=0.03 for 2.5 mg bid and 5 mg bid, respectively. Risk of non-CABG TIMI major bleeding was increased in both oral anticoagulation group, HR=3.46 (2.08–5.77) p<0.001 and HR=4.47 (2.71–7.36) p<0.001 for 2.5 mg bid and 5 mg bid, respectively

Download

Summary

In this ‘Questions to Industry’ Session Bayer’s Vice President of Medical Affairs discusses the role of oral anticoagulation in the long-term management of ACS. Recent data from the ATLAS ACS 2 TIMI 51 trial are presented. In this placebo-controlled trial, Aspirin-only was compared with Aspirin+Rivaroxaban 2.5 mg bid and Aspirin+Rivaroxaban 5 mg bid for secondary prevention of ischaemic events in 15,526 patients post-ACS. 93% of patients were on a concomitant thienopyridine.  Both arms of the Rivaroxaban group saw an improvement in the primary efficacy outcome of CV death, MI or Stroke, HR=0.84 (0.72–0.97) p=0.02 and HR=0.85 (0.73–0.98) p=0.03 for 2.5 mg bid and 5 mg bid, respectively. Risk of non-CABG TIMI major bleeding was increased in both oral anticoagulation group, HR=3.46 (2.08–5.77) p<0.001 and HR=4.47 (2.71–7.36) p<0.001 for 2.5 mg bid and 5 mg bid, respectively

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In